Primary treatment and response in patients with extranodal natural killer (NK)/T-cell lymphoma.

<p>Abbreviations: CRP: C-reactive protein; CT: chemotherapy; RT: radiotherapy; CHOP: cyclophosphamide+doxorubicin+vincristine+prednisone; EPOCH: etoposide+doxorubicin+vincristine+cyclophosphamide+prednisone; ATT: alternating triple therapy (CHOP-B, cyclophosphamide+doxorubicin+vincristine+bleomycin+prednisone; IMVP-16, ifosfamide+methotrexate+etoposide; DHAP, dexamethasone+cisplatin+cytarabine); GEMOX+L-asp: gemcitabine+oxaliplatin+L-asparaginase; SMILE: dexamethasone+methotrexate+ifosfamide+L-asparaginase+etoposide.</p

Univariate and multivariate analysis of prognostic factors for PFS and OS in patients with ENKTL.

<p>Abbreviations: PFS: progression-free survival; OS: overall survival; LN: lymph node; ENKTL: extranodal NK/T-cell lymphoma; RR: relative risk; CI: confidence interval; EUNKTL: extra-upper aerodigestive tract NK/T-cell lymphoma; LDH: lactate dehydrogenase; CRP: C-reactive protein; IPI: International Prognostic Index; KPI: Korean Prognostic Index; ALC: absolute lymphocyte count.</p

Typical distributions of BAFF and BAFF-R expression in follicular lymphoma (FL) and representative cases with different immunostaining intensity for BAFF and BAFF-R.

<p>(A) Distribution of BAFF expression in tumor specimen of FL. (B) Distribution of BAFF-R expression in tumor specimen of FL. (C) Negative staining (−) for BAFF. (D) Weak staining (1+) for BAFF. (E) Moderate staining (2+) for BAFF. (F) Strong staining (3+) for BAFF. (G) Negative staining (−) for BAFF-R. (H) Weak staining (1+) for BAFF-R. (I) Moderate staining (2+) for BAFF-R. (J) Strong staining (3+) for BAFF-R.</p

Survival outcome of patients according to the Korean Prognostic Index (KPI) score.

<p>(A) Overall survival (OS) according to the KPI for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type. (B) OS of patients with KPI score = 0–1 according to the new prognostic index. (C) OS of patients with KPI score = 1–2 according to the new prognostic index. (D) OS of patients with KPI score = 2–4 according to the new prognostic index.</p

Progression-free survival (PFS) and Overall survival (OS) for all 115 patients with follicular lymphoma according to the prognostic scoring system incorporating the 3 independent risk factors for both PFS and OS.

<p>(A) Increasing scores correlated with inferior PFS (<i>P</i><0.001). (B) Increasing scores correlated with inferior OS (<i>P</i><0.001). LR, low risk group (patients with no risk factor); IR, intermediate risk group (patients with 1 risk factor); HR, high risk group (patients with 2–3 risk factors).</p

Survival outcome of patients based on the C-reactive protein (CRP) level.

<p>(A) Progression-free survival (PFS) of patients according to baseline CRP level (≤10 mg/L vs. >10 mg/L). (B) Overall survival (OS) of patients according to baseline CRP level (≤10 mg/L vs. >10 mg/L).</p

Correlation between main clinical features of 115 patients with FL and expression of BAFF and BAFF-R.

<p>FL, follicular lymphoma; BAFF, B-cell activation factor; BAFF-R, B-cell activation factor receptor; ECOG PS, Easter Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; FLIPI, Follicular Lymphoma International Prognostic Index.</p

Survival outcome of patients according to the novel prognostic model.

<p>(A) Overall survival (OS) according to the new prognostic index for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type. (B) OS of patients with low International Prognostic Index risk (IPI score = 0–1) according to the new prognostic index.</p

Overall survival and relative risk of death according to risk group as defined by the new prognostic index.

a<p>Factors: age >60 years, LDH >245 U/l, CRP>10 mg/L, and albumin <35 g/L.</p><p>Abbreviations: OS: overall survival; RR: relative risk; CI: confidence interval; N/A: not applicable.</p

Progression-free survival (PFS) and overall survival (OS) for 115 patients with follicular lymphoma according to BAFF and BAFF-R expression levels.

<p>(A) No significant difference in PFS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.929). (B) No significant difference in OS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.647). (C) Patients with high-BAFF-R expression showed significant inferior PFS (<i>P</i> = 0.013). (D) Patients with high-BAFF-R expression showed significant inferior OS (<i>P</i> = 0.03).</p